AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT00644735
An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 994
- Registration Number
- NCT00643851
- Locations
- 🇺🇸
Southeastern Research Associates, Inc., Greenville, South Carolina, United States
🇺🇸Jackson Clinic, Rolling Fork, Mississippi, United States
🇺🇸Community Health Care, Inc., Canal Fulton, Ohio, United States
Explorative Study of AZD1305 in Atrial Fibrillation Patients
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT00643448
- Locations
- 🇸🇪
Research Site, Goteborg, Sweden
Quality Of Life While Receiving Faslodex
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00643513
- Locations
- 🇷🇺
Research Site, Yakutsk, Russian Federation
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
Phase 2
Completed
- Conditions
- Stable Coronary Artery Disease
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2011-10-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 98
- Registration Number
- NCT00642811
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Children, Perennial Allergic Rhinitis (PAR), l-t Growth
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 209
- Registration Number
- NCT00641212
Factorial Study of Metoprolol Succinate TOPROL-XL (324A)
Phase 3
Completed
- Conditions
- High Blood Pressure (Hypertension).
- Interventions
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1900
- Registration Number
- NCT00642096
Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 380
- Registration Number
- NCT00641472
Inhaled Steroid Treatment as Regular Therapy in Early Asthma
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6800
- Registration Number
- NCT00641914
Quality of Life Validation in Laryngitis
Phase 4
Completed
- Conditions
- Laryngopharyngeal Reflux (LPR)
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT00641264
© Copyright 2025. All Rights Reserved by MedPath